Aldehyde dehydrogenase-1 expression and prognosis in triple-negative breast cancer

Abstract

Objective: Understanding of other biological characteristics of Triple-negative breast cancer, the development of new therapeutical approaches and identification of new markers is necessary due to the lack of biological markers like ER, PR and HER2. The purpose of this study was to investigate the prognostic effect of the expression of aldehyde dehydrogenase-1 (ALDH1) in TNBC and its relationship with the clinico-pathological features Methods: In this study 87 patient files were searched for clinico-pathological data obtained from the files and paraffin blocks. The prognostic value of these clinical data and ALDH1 positivity were evaluated by determining disease-free survival. Results: TNM stage I vs III (p=0.03), vascular invasion (p=0.05), chemotherapy indication (p=0.02) were significantly associated with DFS. Multivariable analyses didn't demonstrate any statistically significant relationship between ALDH1 (p=0.61) and DFS. Conclusions: We didn\'t find any statistically significant relationship between ALDH1 positivity and DFS. There was no correlation between ALDH1 expression and tumor\'s pathological features .

Keywords

• aldehyde dehydrogenase 1, immunohistochemistry, triple-negative breast cancer

Aldehyde dehydrogenase-1 expression and prognosis in triple-negative breast cancer

Öz

References

1. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes-- dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology : official journal of the European Society for
2. Medical Oncology / ESMO. 2011;22(8):1736-47.
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama. 2006;295(21):2492-502.
4. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721-8.
5. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the Epidemiology, and End Results database. Cancer. 2007;110(4):876-84. Institute's Surveillance,
6. Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2008;19(5):861-70.
7. Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, et al. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Annals of surgical oncology. 2011;18(10):2851-7.
8. Zaky SS, Lund M, May KA, Godette KD, Beitler JJ, Holmes LR, et al. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy. Annals of surgical oncology. 2011;18(10):2858-65.

9. Mansour EG, Ravdin PM, Dressler L. Prognostic factors in early breast carcinoma. Cancer. 1994;74(1 Suppl):381- 400.
10. Liu S, Wicha MS. Targeting breast cancer stem cells. Journal of clinical oncology : official journal of the American 2010;28(25):4006-12. Clinical Oncology.
11. Copyright © 2014 The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution
12. License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.